Scopus
YÖKSİS ISSN Eşleşti
SJR Q3
Surveillance of antimicrobial resistance in Gram-negative isolates from intensive care units in Turkey: Analysis of data from the last 5 years
Journal of Chemotherapy · Ocak 2002
Özet
A multicenter antimicrobial surveillance program was established in Turkey in 1995 to monitor the predominant Gram-negative pathogens from intensive care units (ICUs) and antimicrobial resistance patterns of these isolates. Sixteen hospitals participated in the study and a total of 1479 isolates from 1100 patients were collected. The isolates were tested for their susceptibility against 13 antibiotics by E-test method. Minimum inhibitory concentrations (MICs) for each isolate were determined for imipenem, ceftazidime, ceftazidime-clavulanate, cefoperazone-sulbactam, ceftriaxone, cefepime, cefuroxime, piperacillin-tazobactam, ticarcillin-clavulanate, gentamicin, amikacin and ciprofloxacin. The most common isolates were Pseudomonas spp. (28.2%), Escherichia coli (19.2%) and Klebsiella spp. (19.1%). We found very high resistance rates to all major antibiotics that are used to treat serious infections. Although imipenem is the most active agent, it had an overall susceptibility rate of 68%. Half of the tested Klebsiella spp. strains were found to produce ESBL. This is a very high rate when compared with the literature. Cross-resistance among species was also investigated. 52% of ciprofloxacin-resistant strains were also resistant to imipenem, 80% to ceftazidime, 97% to ceftriaxone, 86% to amikacin and 19% of imipenem-resistant strains were susceptible to ceftazidime and 18% to amikacin. When susceptibilities of the years 1995 and 1999 were compared, the most interesting finding was the decrease in resistance to 3rd generation cephalosporins. In conclusion, this national clinical isolate database shows that resistance rates are high, the change over years is not predictable and continuous surveillance is necessary to monitor antimicrobial resistance and to guide antibacterial therapy.
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 4 kaydı bulundu.
YÖKSİS Kayıtları — ISSN Eşleşmesi
Bu dergide (ISSN eşleşmesi) kurumun 4 kaydı bulundu.
Cefiderocol susceptibility in carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria
2026 ISSN: 1120-009X SCI-Expanded Q3
Prof. Dr. HATİCE TÜRK DAĞI →
Cefiderocol susceptibility in carbapenem-resistant
Acinetobacter baumannii
,
Pseudomonas aeruginosa
, and
Stenotrophomonas maltophilia
isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria
2026 ISSN: 1120-009X SCI-Expanded Q3
Prof. Dr. SALİH MAÇİN →
Surveillance of antimicrobial resistance in Gram negative isolates from intensive care units in Turkey Analysis of data from the last 5 years
2002 ISSN: 1120-009X SCI
Prof. Dr. ONUR URAL →
Surveillance of penicillin resistance of Neisseria meningitidis strains from invasive infections between 2013 and 2018 in Turkey
2020 ISSN: 1120-009X SCI-Expanded
Prof. Dr. MELİKE EMİROĞLU →
Makale Bilgileri
Dergi
Journal of Chemotherapy
Toplam Atıf
31 atıf
· Scopus
ISSN1120009X
Yayın TarihiOcak 2002
Cilt / Sayfa14 · 140-146
Scopus ID2-s2.0-0036240866
Kurumlar
Ondokuz Mayis University, Medical School
Samsun Turkey
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 31.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi (ISSN Eşleşmesi)
Journal of Chemotherapy
Q3
SJR Skoru0,525
H-Index60
YayıncıTaylor and Francis Ltd.
ÜlkeUnited Kingdom
Infectious Diseases (Q3)
Medicine (miscellaneous) (Q3)
Oncology (Q3)
Pharmacology (Q3)
Pharmacology (medical) (Q3)
Metrikler
31
Atıf